Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Paula Rodríguez‐Otero
ResearcherPublications, citations & collaboration network
Paula Rodríguez‐Otero is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 684 works, 13,122 citations, an h-index of 57 and an i10-index of 185.
684
Works
13,122
Citations
57
h-index
185
i10-index
How has Paula Rodríguez‐Otero's publication output changed over time?
ScholarIQpublication output · 2009–2023
Output grew300% over the shown period — from 1 works in 2009 to 4 in 2023.
1
4
2
4
2009201920222023
What are the most-cited papers on Paula Rodríguez‐Otero?
ScholarIQmost cited works
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward N. Libby, Bertrand Arnulf, Thierry Façon, Cyrille Hulin, K. Martin Kortüm, Paula Rodríguez‐Otero, Saad Z. Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M. Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen
The Lancet Oncology. 2019806 Citations
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesús G. Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre‐Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
New England Journal of Medicine. 2023733 CitationsOPEN ACCESS
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Ajai Chari, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, Elham Askari, María‐Victoria Mateos, Luciano J. Costa, Jo Caers, Raluca Verona, Suzette Girgis, Shiyi Yang, Rachel B. Goldsmith, Xiang Yao, Kodandaram Pillarisetti, Brandi Hilder, Jeffery S. Russell, Jenna D. Goldberg, Amrita Krishnan
New England Journal of Medicine. 2022676 CitationsOPEN ACCESS
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf, Nizar J. Bahlis, H. Miles Prince, Rubén Niesvizky, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Guenther Koehne, Cyrille Touzeau, Yogesh Jethava, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Afshin Eli Gabayan, Don A. Stevens, Ajay K. Nooka, Salomon Manier, Noopur Raje, Shinsuke Iida, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Umberto Conte, Mohamed Elmeliegy, Akos Czibere, Andrea Viqueira, Mohamad Mohty
Nature Medicine. 2023592 CitationsOPEN ACCESS
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Juul Vangsted, Hermann Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau
New England Journal of Medicine. 2023537 CitationsOPEN ACCESS
Related on ScholarIQ
Navarre Institute of Health Research
Institution
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Paper
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paper
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Paper
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Paper
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Paper